Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

BackgroundStarting in 2010, the epidermal growth factor receptor (EGFR) kinase inhibitors erlotinib and gefitinib were introduced into routine use in Aotearoa New Zealand (NZ) for treating advanced lung cancer, but their impact in this setting is unknown. Objectiv...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Phyu Sin Aye, Joanne Barnes, George Laking, Laird Cameron, Malcolm Anderson, Brendan Luey, Stephen Delany, Dean Harris, Blair McLaren, Elliott Brenman, Jayden Wong, Ross Lawrenson, Michael Arendse, Sandar Tin Tin, Mark Elwood, Philip Hope, Mark James McKeage
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	JMIR Publications 2024-07-01
Serie:	JMIR Research Protocols
Accesso online:	https://www.researchprotocols.org/2024/1/e51381
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!